Verge Genomics
2015
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Series A1
LATEST DEAL TYPE
21
INVESTORS
Description
Developer of a drug discovery platform designed to reduce the time and cost of drug discovery. The company's platform utilizes machine learning to develop new therapeutics and is specifically designed for neurological diseases, and can analyze thousands of datasets to identify new targets, predict effective drugs and stratify patient subpopulations, enabling healthcare providers to improve patient outcomes as well as fundamentally bend the cost curve of pharmaceutical development.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Drug Discovery
Primary Office
- Two Tower Place
- Suite 950
- San Francisco, CA 94080
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Verge Genomics’s full profile, request a free trial.
Verge Genomics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A1) | 25-Jan-2019 | 000.00 | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series A) | 16-Jul-2018 | 0000 | 000.00 | 0000 | Completed | Generating Revenue |
| 2. Seed Round | 28-Oct-2015 | $4M | $4.12M | Completed | Startup | |
| 1. Accelerator/Incubator | 18-Aug-2015 | $120K | $120K | 00.000 | Completed | Startup |
Verge Genomics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A6 | 000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A5 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A4 | 00,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A3 | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.00 |
| Series A2 | 1,698,104 | $0.001000 | 6% | $2.65 | $2.65 | 1x | $2.65 | 8.37% |
| Series A1 | 8,502,149 | $0.001000 | 6% | $3.31 | $3.31 | 1x | $3.31 | 34.94% |
Verge Genomics Competitors (37)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Relay Therapeutics | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| 00 000000000000 | Venture Capital-Backed | Guilford, CT | 00 | 0000 | 00000000000 | 0000 |
| 00000000 000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 | Venture Capital-Backed | Framingham, MA | 0 | 0000 | 0000000000 0 | 0000 |
| 00000000 | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
Verge Genomics Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| ALS Investment Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Basis Set Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Lifeforce Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| OS Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Threshold Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Verge Genomics Executive Team (7)
1 Former Executive
You’re viewing 5 of 7 executives. Get the full list »Verge Genomics Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alice Zhang Ph.D | Verge Genomics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 | |
| Dave Madge | WuXi AppTec | Board Member | 000 0000 | |
| Emily Melton | Verge Genomics | Board Member | 000 0000 | |
| Melanie Leitner Ph.D | ALS Investment Fund | Board Member | 000 0000 |